Provided by Tiger Trade Technology Pte. Ltd.

Merck

147.76
-0.5900-0.40%
Post-market: 148.470.7090+0.48%19:58 EDT
Volume:11.13M
Turnover:1.64B
Market Cap:364.55B
PE:116.09
High:148.69
Open:147.00
Low:145.95
Close:148.35
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.03
T/O Rate:0.45%
Dividend:3.32
Dividend Rate:2.25%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.69
PE(LYR):20.30

Loading ...

Merck Says Keytruda Monotherapy Improves PFS in Phase 3 Trial for Dmmr Endometrial Cancer

Reuters
·
Jul 15

Keytruda® (pembrolizumab) as Monotherapy Significantly Improved Progression-free Survival (pfs) in Certain Patients with Advanced or Recurrent Endometrial Cancer with Mismatch Repair Deficient (dmmr) Tumors Compared to Chemotherapy

THOMSON REUTERS
·
Jul 15

Merck & Co - Phase 3 Keynote-c93 Trial Meets Primary Endpoint of Progression-free Survival

THOMSON REUTERS
·
Jul 15

Merck & Co - Interim Analysis Shows Trend Toward Improved Os for Keytruda; Os Data not Mature

THOMSON REUTERS
·
Jul 15

Merck & Co - Keytruda Safety Profile Consistent with Previous Studies; no New Safety Signals Identified

THOMSON REUTERS
·
Jul 15

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Annexon Biosciences (ANNX) and Guardant Health (GH)

TIPRANKS
·
Jul 15

Zoetis Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 15

Movement Alert|Merck Drops 3.03% in Regular Trading, Trading at $120.42

Market Focus
·
Jul 15

Dow's 159-point Drop Led by Losses in Shares of IBM, Merck

Dow Jones
·
Jul 14

Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug

MT Newswires Live
·
Jul 14

Merck is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 13

JPMorgan Adjusts Price Target on Merck to $140 From $135, Maintains Overweight Rating

MT Newswires Live
·
Jul 13

Merck & Co. Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 11

Merck confirms FDA approves Keytruda combos with Padcev

TIPRANKS
·
Jul 11

FDA Approves Keytruda® (pembrolizumab) and Keytruda Qlex™ (pembrolizumab and Berahyaluronidase Alfa-pmph), Each with Padcev® (enfortumab Vedotin-ejfv), as Treatment Before and After Surgery for Adults with Muscle-invasive Bladder Cancer (mibc)

THOMSON REUTERS
·
Jul 11

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer

MT Newswires Live
·
Jul 10

FDA approves Keytruda combos for certain muscle invasive bladder cancer cases

TIPRANKS
·
Jul 10

FDA Approves Pembrolizumab Combination for Muscle Invasive Bladder Cancer

Reuters
·
Jul 10

FDA: Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Jul 10